Mankind Pharma

Delhi, India Founded: 1991 • Age: 35 yrs Listed Fortune India 500 · #210
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations
Request Access
Report Incorrect Data
Page last updated

About Mankind Pharma

Mankind Pharma is a publicly listed company based in Delhi (India) founded in 1991 by Greesh Juneja, Ramesh Chand Juneja, Ramesh Juneja, and Rajeev Juneja. Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. Mankind Pharma has raised $367.2 million across 2 funding rounds from investors including ChrysCapital and Monet. The company has 21,320 employees. Mankind Pharma has completed 2 acquisitions, including BSV Group and Upakarma. Mankind Pharma was last valued at $216.5 million in April 2007. Its chief executive, as recorded, is Sheetal Arora. Its website mankindpharma.com draws about 93 thousand monthly visits. Its Indian entity Mankind Pharma Limited reported revenue of ₹14,648 Cr. Mankind Pharma offers products and services including Formulations and Consumer Healthcare Products. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Established in 1991 and headquartered in Delhi, India, the pharmaceutical company is involved in the development, manufacturing, and marketing of formulations targeting multiple therapeutic areas. These include anti-infectives, cardiovascular, gastrointestinal, respiratory, vitamins, minerals, nutrients, anti-diabetic, neurocentral nervous system, and gynaecology segments. Both acute and chronic conditions are addressed through brands such as Nurokind, Telmikind, Moxikind, Amlokind, and Gudcef.

Mankind Pharma is ranked #210 on the Fortune India 500 (2025).

Recognitions & Rankings of Mankind Pharma

Fortune India 500 2025 edition
Rank#210
Total income
₹12,944 Cr
Profit
₹1,991 Cr
Last year #227
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#60
Valuation
₹1,05,770 Cr
2023 #60 2022 #84 2021 #109
  • Headquarters Delhi, India
  • Employees 21,320
  • Founders Greesh Juneja, Ramesh Chand Juneja, Ramesh Juneja, Rajeev Juneja
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website mankindpharma.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Mankind Pharma Ltd.
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹93,993 Cr

    MANKIND · NSE

  • Share Price
    ₹2,212.60

    -2.77% today

  • Revenue
    ₹14,278 Cr

    FY 2025-26 · +17.0% YoY

  • EBITDA
    ₹3,493 Cr

    Margin 24.5%

  • Net Profit
    ₹2,014 Cr

    FY 2025-26 · +12.2% YoY

  • P/E (TTM)
    44.3x

    P/B 5.8x

  • ROE
    12.7%

    ROCE 13.0%

  • Debt / Equity
    0.48

    Interest cover 24.7x

  • Total Equity Funding
    $367.2M (USD)

    in 2 rounds

  • Latest Funding Round
    $350M (USD), Private Equity Round

    Apr 2018

  • Investors
    ChrysCapital

    & 1 more

  • Employee Count
    21,320
  • Investments & Acquisitions
    BSV Group

    & 1 more

Products & Services of Mankind Pharma

Mankind Pharma offers a comprehensive portfolio of products and services, including Formulations and Consumer Healthcare Products.

Formulations
Pharmaceutical Products

A range of pharmaceutical formulations across acute and chronic therapeutic areas is developed and marketed to address patient needs.

Consumer Healthcare Products
OTC Products

Products for the non-prescription segment, such as antacids and condoms, are offered to meet everyday healthcare requirements.

Apps and channels of Mankind Pharma

its YouTube channel Mankind Pharma has 108K subscribers and 30 videos.

Mankind Pharma
YouTube 108K subscribers 30 videos Science & Technology
Open channel

Videos from Mankind Pharma

The most watched videos on Mankind Pharma's YouTube channel, Mankind Pharma (108K subscribers). Click a video to play it here.

Those Who Chose Duty Over All Else | Doctor's Day 2025 | Mankind Pharma
4.8M views
World Organ Donation Day | 13th August | Hindi | Share the Gift of Life | Ft. Amitabh Bachchan
3M views
Those Who Chose Duty Over All Else | Doctor's Day 2025 | Mankind Pharma
919.9K views
World Organ Donation Day | 13th August | Marathi | Share the Gift of Life | Ft. Amitabh Bachchan
311.2K views

More on Mankind Pharma.

Funding Insights of Mankind Pharma

Mankind Pharma has successfully raised a total of $367.2M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $350 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $367.2M
  • Total Rounds 2
  • Last Round Private Equity Round — $350M
  • First Round $17.2M

    (Apr 2007)

  • Investors Count 2

All 2 funding rounds of Mankind Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2018$350MPrivate Equity Round–ChrysCapital
–
Apr 2007$17.2MSeries A$216.5MMonet
–
Valuation history
DateValuationStage
Apr 2007$216.5M••••••••

Last known valuation $216.5M (Apr 2007). 2 investors in total: 2 institutional.

Investors in Mankind Pharma

Mankind Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include ChrysCapital and Monet.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
ChrysCapital
Investment firm focusing on private equity in sectors like financial services and healthcare.
1999chryscapital.com
Monet
monet.tcc.mode
Premium access

Investor details for Mankind Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Mankind Pharma Limited (Mankind Pharma)

Mankind Pharma Limited is the primary company behind Mankind Pharma. The board of Mankind Pharma Limited currently have 8 directors; the longest-serving is Ramesh Juneja, appointed in 1991. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramesh Juneja
DIN 00283399
Whole-time director03 Jul 199135 yrs 3 moMankind Pharma Limited
Rajeev Juneja
DIN 00283481
Managing Director22 Dec 199233 yrs 10 moMankind Pharma Limited
Sheetal Arora
DIN 00704292
Whole-time director21 Sep 200719 yrs 1 moMankind Pharma Limited
Satish Kumar Sharma
DIN 07615602
Whole-time director23 Sep 201610 yrs 1 moMankind Pharma Limited
Tilokchand Punamchand Ostwal
DIN 00821268
Director01 Jan 20206 yrs 9 moMankind Pharma Limited
Vijaya Sampath
DIN 00641110
Director01 Aug 20224 yrs 2 moMankind Pharma Limited
Vivek Kalra
DIN 00426240
Director01 Aug 20224 yrs 2 moMankind Pharma Limited
Anish Vanraj Bafna
DIN 02925792
Director10 Aug 20262 moMankind Pharma Limited

People of Mankind Pharma

143 people are tracked at Mankind Pharma (45 in leadership, 98 in team); the tracked headcount is 21,320.

NameRoleGroup
Greesh Juneja
Co-FounderLeadership
Ramesh Chand Juneja
Co-FounderLeadership
Ramesh Juneja
Co-FounderLeadership
Rajeev Juneja
Co-Founder & Managing DirectorLeadership
Sheetal Arora
CEOLeadership
Dr.taj Shinwari
Business Unit HeadLeadership
Dr. Chhavi Sandhu
Assistant General ManagerLeadership
Santosh Soni
Deputy General Manager (information Service)Leadership
Alpesh R. Patel
Assistant General ManagerLeadership
Yogendra Upadhyay
Assistant General Manager OperationsLeadership
Paramvir Bhasin
Deputy General Manager- Finance & AccountsLeadership
Arjun Juneja
Chief Operating OfficerLeadership
Dr Piyush Prashant
Vice President , Pet Mankind And Pet FoodLeadership
Soumya Panda
Senior Vice President OperationsLeadership
Paras Nath Singh
Senior General ManagerLeadership
Pradip Pal
Deputy General ManagerLeadership
Prashant Katiyar
General Manager - Business Transformation & Operational Excellence (coo's Office)Leadership
Eshwar Chandra
General Manager- Global SourcingLeadership
Rakesh Sharma
General Manager -operationsLeadership
Patan Moyeen Abdulla Khan
Sales Head - APLeadership

123 more people are available in the full profile.

Premium access

Complete people profiles for Mankind Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Mankind Pharma

Mankind Pharma is a publicly listed company on the NSE with ticker symbol MANKIND in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date09 May 2023
  • Listed onBSE: 543904 · NSE: MANKIND
  • Listed entityMankind Pharma Ltd.
  • Exchange sectorHealth technology
  • ISININE634S01028
  • Share price₹2,335.00 (-1.56% on the day) · 2026-10-14
  • Market capitalisation₹97,850 Cr
  • Price to earnings47.2
  • EPS (diluted, trailing year)₹49.42
  • Dividend yield0.04%
  • Volume (last session)498,153

Financials of Mankind Pharma

Exchange-reported figures of Mankind Pharma Limited, the listed company behind Mankind Pharma (NSE: MANKIND).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹14,278 Cr
+17.0% YoY
EBITDA
₹3,493 Cr
+15.6% YoY
Profit After Tax
₹2,014 Cr
+12.2% YoY
Net Worth
₹16,300 Cr
+13.7% YoY
Total Assets
₹23,151 Cr
-0.4% YoY
Total Debt
₹6,312 Cr
-25.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Balance sheet
Total assets23,15123,2559,9297,9177,2905,1853,884
Net worth16,30014,3329,3637,4356,1554,7223,485
Total debt6,3128,511207170873241131
Cash & bank483554708453406701420
Net working capital2,3292,6052,3651,5311,7301,426976
Cash flow
Cash from operations3,1212,4132,1521,8139201,1371,070
Cash from investing(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Cash from financing(2,953)10,2335.27(740)605(7.81)(531)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%---
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Balance sheet
Total assets22,19421,8379,8517,8987,3174,8983,715
Net worth16,39714,3239,7037,7846,5404,7343,651
Total debt5,5717,38323.504.696881012.56
Cash & bank159306484155139477198
Net working capital7035581,7911,0381,3611,212739
Cash flow
Cash from operations2,7522,3501,7361,7998211,022960
Cash from investing(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Cash from financing(2,477)9,816(4.73)(710)57988.87(559)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%---
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%---
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
Other income370554296141210183122
Total expenses10,7859,1877,7456,8485,7914,5654,427
Employee cost3,1842,6922,2611,9181,6211,4161,336
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Depreciation88662137832616711999.06
Interest64443234.2445.7659.8021.1623.24
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Tax395510457362522399382
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,25914,2919,3237,3956,1154,6823,445
Shareholders' funds (net worth)16,30014,3329,3637,4356,1554,7223,485
Minority interest261236213188161141186
Secured loans5,7656,026196163804224114
Unsecured loans5472,48511.137.7368.7517.1416.68
Total debt6,3128,511207170873241131
Total liabilities23,15123,2559,9297,9177,2905,1853,884
Assets
Gross block21,37720,9175,9155,2394,2522,1661,993
Net block18,62019,0054,5454,2513,5881,6641,600
Capital work in progress1,128826282550701372317
Investments1,9852,0422,5681,3461,1091,512829
Inventories2,1442,0941,5531,4981,7601,184899
Sundry debtors1,7301,538848576388331531
Cash & bank balances483554708453406701420
Loans & advances1,0601,1111,200724978386307
Total current assets5,4175,2974,3103,2523,5322,6002,157
Total current liabilities3,0882,6921,9451,7211,8031,1751,181
Net working capital2,3292,6052,3651,5311,7301,426976
Total assets23,15123,2559,9297,9177,2905,1853,884
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash404382305283127220116
Net cash from operating activities3,1212,4132,1521,8139201,1371,070
Net cash from investing activities(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Net cash from financing activities(2,953)10,2335.27(740)605(7.81)(531)
Net change in cash(12.19)21.8777.1921.76156(92.40)103
Closing cash483554708453406701420
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
EBITDA growth+15.6%+20.1%+32.2%-4.5%+20.7%+14.7%-
PBT growth-7.5%+5.1%+43.5%-15.4%+16.7%+17.7%+131.5%
Net income growth+12.2%-0.6%+44.2%-8.5%+12.5%+22.0%-
Revenue CAGR (3Y)+17.7%+16.2%+18.2%+14.3%+32.7%--
EBITDA CAGR (3Y)+22.5%+14.9%+15.1%+9.8%+50.3%--
Profitability & leverage
Net income margin+13.6%+16.5%+18.9%+15.0%+18.7%+20.8%+18.0%
Return on capital employed+13.0%+18.0%+27.9%+23.1%+33.4%+39.2%+39.5%
Return on net worth+12.7%+17.0%+23.1%+19.3%+26.7%+31.5%+30.3%
Debt / equity0.480.370.020.080.100.050.04
Long-term debt / equity0.280.240.000.010.010.010.01
Interest cover24.7218.001.602.903.281.381.74
Efficiency & per share
Fixed asset turnover0.680.911.841.842.432.992.94
Inventory turnover6.746.696.725.375.295.976.52
Debtors turnover8.7410.2314.4018.1421.6514.4211.04
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Dividend per share (₹)1.000.000.000.000.007.600.00
Book value per share (₹)16,301.46347.37233.73185.61153.65117.8887.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%---
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
Other income32655537416320414893.85
Total expenses7,4417,0826,3626,4295,6484,1513,550
Employee cost2,3672,1491,9211,7011,4631,106991
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Depreciation42939533527012378.1961.77
Interest56237816.9328.2347.548.2311.10
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Tax277422413315482356307
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,35614,2819,6637,7446,5004,6943,611
Shareholders' funds (net worth)16,39714,3239,7037,7846,5404,7343,651
Secured loans5,4885,44414.930.0062495.000.00
Unsecured loans82.521,9398.574.6964.235.852.56
Total debt5,5717,38323.504.696881012.56
Total liabilities22,19421,8379,8517,8987,3174,8983,715
Assets
Gross block5,8915,6584,5783,7763,2921,2271,117
Net block3,9264,0763,5523,1422,927987945
Capital work in progress420207209495387166148
Investments16,52316,6834,2153,1022,5262,3971,784
Inventories1,0881,0981,1261,0321,267827533
Sundry debtors1,164909769493471369419
Cash & bank balances159306484155139477198
Loans & advances7248491,0117751,071521404
Total current assets3,1353,1623,3902,4552,9472,1941,554
Total current liabilities2,4322,6041,5991,4181,586982816
Net working capital7035581,7911,0381,3611,212739
Total assets22,19421,8379,8517,8987,3174,8983,715
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash20121214586.1746.3677.5072.48
Net cash from operating activities2,7522,3501,7361,7998211,022960
Net cash from investing activities(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Net cash from financing activities(2,477)9,816(4.73)(710)57988.87(559)
Net change in cash(113)(10.96)66.1647.9639.81(15.96)5.02
Closing cash159306484155139477198
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
EBITDA growth+22.9%+7.0%+33.5%-7.7%+33.4%+10.8%-
PBT growth+4.9%-3.5%+46.5%-16.5%+29.9%+13.9%+83.0%
Net income growth+32.4%-9.3%+45.2%-8.2%+25.9%+12.2%-
Revenue CAGR (3Y)+8.6%+8.3%+16.0%+19.2%+25.0%+12.2%+11.1%
EBITDA CAGR (3Y)+20.6%+9.7%+18.0%+10.9%+37.7%+21.0%+21.1%
Profitability & leverage
Net income margin+19.6%+18.8%+21.7%+15.4%+18.6%+19.6%+20.0%
Return on capital employed+13.1%+16.3%+23.4%+20.9%+31.4%+33.6%+36.4%
Return on net worth+13.3%+14.9%+20.3%+17.4%+24.7%+25.9%+28.5%
Debt / equity0.420.310.000.050.070.010.03
Long-term debt / equity0.250.210.000.000.000.000.00
Interest cover22.0518.590.881.982.770.630.94
Efficiency & per share
Fixed asset turnover1.801.862.072.303.314.724.77
Inventory turnover9.548.558.007.077.158.139.45
Debtors turnover10.0611.3313.6816.8717.8314.0417.19
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Dividend per share (₹)1.000.000.000.000.000.007.55
Book value per share (₹)397.21347.13242.21194.31163.27118.1891.15

Investments & Acquisitions by Mankind Pharma

Mankind Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BSV Group and Upakarma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
BSV Group
Provider of drug research & development services for pharmaceutical sector
bsvgroup.comMumbai, India1971Jul 2024••••
Upakarma
Internet first D2C brand offering ayurvedic health, beauty, immunity & wellness products
upakarma.comDelhi, India2017Nov 2022••••
Premium access

Complete acquisition details for Mankind Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Mankind Pharma

7 dated milestones of Mankind Pharma across 33 years, from founding to its latest funding, stage changes and deals.

  1. Founded Mankind Pharma is founded.
  2. Funding First funding round of $17.2M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Private Equity Round, of $350.0M.
  5. Acquisition Acquires Upakarma.
  6. IPO Lists on the stock exchange (IPO).
  7. Acquisition Acquires BSV Group.

Web traffic of Mankind Pharma

The website of Mankind Pharma (mankindpharma.com) receives about 92.6K visits a month.

  • Monthly visits
    92.6K

    ▲ 36.1% vs previous month

Similar websites

Websites whose visitors overlap most with Mankind Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Piramal Pharma
piramalpharma.com
100%
19.3K#1,449,631View details
easyofficesoftware.com
easyofficesoftware.com
86%
#1,130,471–
MarketsMojo
marketsmojo.com
86%
834.5K#72,195View details
sharescart.com
sharescart.com
86%
#270,665–
GEPL Capital
geplcapital.com
86%
11.3K#1,657,836View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Mankind Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Mankind Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Mankind Pharma

Mankind Pharma: Board Approves Investment of Up to €45 Million in Mankind Netherlands and Plans to Buy 70% Stake in Armed Cell Therapeutics for €48 Million.
Exchange Update • 10 days ago
MANKIND: Rs. 46.93 Crores BSE Block Trade; for ~ 196,108 Shares, at Rs. 2393.15
Exchange Update • 12 days ago
Mankind Pharma: Kotak Inst Eqt on Mankind Pharma Upgrades to Buy with Target Price of ₹3,000 as domestic business recovery accelerates with 14.6% YoY July/August sales growth, 120 bps outperformance versus IPM, improving market shares, stable field force, higher R&D and new launches, supporting ~23% FY26–29E EPS CAGR.
Exchange Update • 1 month ago
Mankind Pharma Ltd.: Rs. 28.49 Crores NSE Block Trade; for ~ 125,112 Shares, at Rs. 2276.90
Exchange Update • 1 month ago
Mankind Pharma: Gets ESG Rating Of 68.21 From Niche99 In Leader Category For FY26
Exchange Update • 1 month ago
Mankind Pharma Launches "Angdaan Mahadaan" to Inspire 1 Crore Indians to Pledge for Organ Donation
OdishaDiary • 1 month ago
Mankind Pharma divests entire stake in Broadway Hospitality to AKRK Projects - The Economic Times
Economic Times • 1 month ago
Why has the Centre barred certain cold medicines for children under four?
Mint • 2 months ago
Mankind Pharma shares fall over 2% to Rs 2,373.80
Moneycontrol • 2 months ago
Mankind Pharma shares gain 2% in today's session
Moneycontrol • 2 months ago
Premium access

Complete news archive for Mankind Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Mankind Pharma on our blog

Frequently Asked Questions about Mankind Pharma

Mankind Pharma was founded in 1991 and raised its 1st funding round 16 years after it was founded.

Mankind Pharma is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

Sheetal Arora is the CEO of Mankind Pharma, as recorded in our data.

Mankind Pharma is a funded company, having raised a total of $367.2M across 2 funding rounds to date. The company's 1st funding round was a Series A of $17.2M, raised on Apr 2007.

Mankind Pharma has 21,320 employees.

The primary company behind Mankind Pharma, Mankind Pharma Limited, reported revenue of ₹14,648 Cr for FY 2026, up 17% year on year.

Established in 1991 and headquartered in Delhi, India, the pharmaceutical company is involved in the development, manufacturing, and marketing of formulations targeting multiple therapeutic areas. These include anti-infectives, cardiovascular, gastrointestinal, respiratory, vitamins, minerals, nutrients, anti-diabetic, neurocentral nervous system, and gynaecology segments. Both acute and chronic conditions are addressed through brands such as Nurokind, Telmikind, Moxikind, Amlokind, and Gudcef.

Mankind Pharma offers Formulations and Consumer Healthcare Products.

Yes, Mankind Pharma is publicly traded on NSE under the ticker symbol MANKIND.

Mankind Pharma has made 2 acquisitions, including BSV Group, and Upakarma.

Mankind Pharma has 2 investors. Key investors include ChrysCapital, and Monet.

The valuation of Mankind Pharma is $216.5M as of Apr 2007.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available